SaxoCell Cluster is entering its third funding phase for the Cell and Gene Therapy industry.
Public source
Publisher name
Public post
๐ฌ๐ผ๐๐ฟ ๐ถ๐ฑ๐ฒ๐ฎ ๐ฐ๐ผ๐๐น๐ฑ ๐ฏ๐ฒ๐ฐ๐ผ๐บ๐ฒ ๐๐ต๐ฒ ๐ป๐ฒ๐ ๐ ๐ฏ๐ฟ๐ฒ๐ฎ๐ธ๐๐ต๐ฟ๐ผ๐๐ด๐ต ๐ถ๐ป ๐๐ฒ๐น๐น & ๐๐ฒ๐ป๐ฒ ๐ง๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐. SaxoCell Cluster is entering its ๐ฏ๐ฟ๐ฑ ๐ณ๐๏ฟฝโฆ
Company
SaxoCell Cluster
Living Drugs - The Saxon Precision Therapy Cluster
- Industry
- Biotechnology Research
- Location
- Leipzig, DE
- Company size
- 2โ10 employees
About SaxoCell Cluster
Hi there, we are SaxoCellยฎ - the Saxon innovation cluster in the area of cell and gene therapy (CGT) founded by the #BMBF #clusters4future initiative. Together with many academic and corporate partners, we aim to develop and improve CGT-based therapies to treat serious, predominantly tumor and autoimmune diseases, for which there is not yet a suitable cure.
See moreLatest activity
Latest activity from SaxoCell Cluster
5 signals
Presence & Recognition
SaxoCell Cluster announced the introduction of the B:Clubs for the new season at the Staatsschauspiel Dresden on September 7, 2026.
Presence & Recognition
SaxoCell Cluster is featured in a symposium hosted by Cytiva and Fraunhofer IZI on 20th September 2026 at the Fraunhofer IZI facility in Leipzig.
Presence & Recognition
SaxoCell Cluster participated in the 10th anniversary edition of Dresden's Neumarkt event on Monday, 2026.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine reported seven approvals between the United States and the European Union for its near-term cell and gene therapy pipeline in 2026.
Capital & Finance
BioInnovation Institute (BII)
BioInnovation Institute (BII) doubles down on 6 companies and adds โฌ 8 million in total support.
Capital & Finance
BioM Biotech Cluster Development GmbH
BioM Biotech Cluster Development GmbH secured EUR 2.2 million in fresh seed funding, paid industrial pilot projects, and a licensing model enabling local enzyme production for Twogee.
Capital & Finance
Camelot BioCapital
Camelot BioCapital reported eight deals up to $19 billion in CAR-T and in vivo CAR-T cell therapy, with zero of the eight showing a way to switch the cells off once they're in.
Capital & Finance
TILT Biotherapeutics Ltd